Multiple Myeloma Pipeline 2025: Key Clinical Innovations from Over 75 Global Leaders - DelveInsight | Highlighted companies include CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics,

DelveInsight's, "Multiple Myeloma Pipeline Insight, 2025," report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Multiple Myeloma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
With multiple myeloma increasingly affecting populations worldwide and contributing to comorbidities such as diabetes, cardiovascular disease, and certain cancers, the demand for safer and more effective treatments continues to grow. According to DelveInsight, the multiple myeloma pipeline includes over 75 pharmaceutical and biotech companies developing more than 80 therapeutic candidates. These therapies are at various stages of clinical and preclinical development, reflecting significant innovation and dedication to addressing this critical public health challenge.

DelveInsight's "Multiple Myeloma Pipeline Insight 2025" report provides a comprehensive and strategic assessment of the R&D landscape. It examines clinical trial progress, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. The report is an essential resource for stakeholders-including researchers, healthcare investors, and decision-makers-seeking insights into the evolving multiple myeloma therapeutics market and the innovations shaping its future.

Explore the Cutting-Edge Landscape of Multiple Myeloma Drug Development [https://www.delveinsight.com/report-store/multiple-myeloma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Key Takeaways from the Multiple Myeloma Pipeline Report

*
DelveInsight's Multiple Myeloma pipeline report highlights a vibrant landscape with over 75 active companies developing more than 80 therapeutic candidates for multiple myeloma treatment.

*
In April 2024, a therapy was approved for adult patients with relapsed or refractory multiple myeloma who had received at least one prior treatment, including a proteasome inhibitor and an immunomodulatory agent, and were refractory to lenalidomide. Approval was supported by Phase 3 CARTITUDE-4 study data, showing a 59% reduction in the risk of disease progression or death compared to standard therapies.

*
In March 2024, an FDA advisory panel unanimously endorsed the expanded use of Carvykti Registered as an earlier-line treatment for multiple myeloma, while support for Abecma Registered was mixed, with eight out of eleven panel members favoring its earlier use.

*
Key companies advancing multiple myeloma therapies include CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai, Sorrento Therapeutics, TeneoOne, Karyopharma Therapeutics, Arcellx, Poseida Therapeutics, Ichnos Sciences, Nerviano Medical Sciences, Bristol Myers Squibb, Ascentage Pharma, Ionis Pharmaceuticals, Chongqing Precision Biotech, CRISPR Therapeutics, AstraZeneca, IGM Biosciences, Novartis, GlaxoSmithKline, Innovent Biologics, Keymed Biociences, Starton Therapeutics, Takeda, Fate Therapeutics, Gilead Sciences, Jiangsu Chia Tai Fenghai Pharmaceutical, Janssen Pharmaceutical, Nanjing IASO Biotechnology, GPCR Therapeutics, Chimerix, and others, all working to advance the treatment landscape.

*
Promising pipeline candidates at various stages include Zevorcabtagene Autoleucel, Descartes 08, GC012F, CID-103, STI-1492, and several others.

Multiple Myeloma Overview:

Multiple myeloma (MM) is a condition characterized by the clonal expansion of plasma cells, leading to an abnormal increase in monoclonal immunoglobulins. If unchecked, this excessive plasma cell growth can result in organ damage, commonly presenting as hypercalcemia, kidney dysfunction, anemia, or bone pain associated with lytic lesions.

Download the Multiple Myeloma sample report to know in detail about the Multiple Myeloma treatment market @ https://www.delveinsight.com/sample-request/multiple-myeloma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Multiple Myeloma Pipeline Analysis

The Multiple Myeloma pipeline insights report 2025, provides insights into:

*
Provides comprehensive insights into key companies developing therapies in the Multiple Myeloma Market.

*
Categorizes Multiple Myeloma therapeutic companies by development stage: early, mid, and late-stage.

*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

*
Reviews emerging Multiple Myeloma drugs under development based on:

*
Stage of development

*
Multiple Myeloma Route of administration

*
Target receptor

*
Monotherapy vs. combination therapy

*
Multiple Myeloma Mechanism of action

*
Molecular type

*
Offers detailed analysis of:

*
Company-to-company and company-academia collaborations

*
Multiple Myeloma Licensing agreements

*
Funding and investment activities supporting future Multiple Myeloma market advancement.

Unlock key insights into emerging Multiple Myeloma therapies and market strategies here: https://www.delveinsight.com/report-store/multiple-myeloma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Multiple Myeloma Emerging Drugs

*
Zevorcabtagene Autoleucel: Carsgen Therapeutics

Zevorcabtagene Autoleucel (Zevor-cel, R&D code: CT053) is an autologous, fully human CAR T-cell therapy targeting B-cell maturation antigen (BCMA) for the treatment of relapsed/refractory multiple myeloma (R/R MM). In October 2022, China's National Medical Products Administration (NMPA) accepted its New Drug Application (NDA) and granted it priority review. Zevor-cel is expected to receive NMPA approval for R/R MM by late 2023 or early 2024. In January 2023, CARsgen partnered with Huadong Medicine to commercialize Zevor-cel in mainland China, and the two companies have since been working closely to support the approval process and prepare for its market launch.

*
Descartes 08: Cartesian Therapeutics

Descartes-08 is an autologous RNA-modified CAR T-cell therapy targeting BCMA. It is generated via mRNA transfection, allowing temporary expression of the anti-BCMA CAR for about one week, which helps minimize the risk of uncontrolled cell proliferation. The therapy triggers the release of inflammatory cytokines in response to myeloma cells and exhibits potent cytolytic activity, even in the presence of protective bone marrow stromal cells, proliferation-inducing ligands, or drug resistance mechanisms such as IMiDs. The degree of tumor cell destruction correlates with the duration of CAR expression, highlighting its time-limited activity. Early clinical studies indicate that Descartes-08 is safe and well-tolerated in patients with monoclonal gammopathy (MG) and multiple myeloma. The therapy is currently in Phase II clinical development for multiple myeloma.

*
GC012F: Gracell Biotechnology Shanghai Co., Ltd.

*
CID-103: CASI Pharmaceuticals

*
STI-1492: Sorrento Therapeutics

Multiple Myeloma Pipeline Therapeutic Assessment

Multiple Myeloma Assessment by Product Type

- Mono

- Combination

- Mono/Combination

Multiple Myeloma By Stage

- Late-stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

Multiple Myeloma Assessment by Route of Administration

- Oral

- Parenteral

- Intravenous

- Subcutaneous

- Topical

Multiple Myeloma Assessment by Molecule Type

- Recombinant fusion proteins

- Small molecule

- Monoclonal antibody

- Peptide

- Polymer

- Gene therapy

Download sample pages to get an in-depth assessment of the emerging Multiple Myeloma therapies and key Multiple Myeloma companies [https://www.delveinsight.com/sample-request/multiple-myeloma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Contents

1. Report Introduction

2. Executive Summary

3. Multiple Myeloma Current Treatment Patterns

4. Multiple Myeloma - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Multiple Myeloma Late-Stage Products (Phase-III)

7. Multiple Myeloma Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Multiple Myeloma Discontinued Products

13. Multiple Myeloma Product Profiles

14. Multiple Myeloma Key Companies

15. Multiple Myeloma Key Products

16. Dormant and Discontinued Products

17. Multiple Myeloma Unmet Needs

18. Multiple Myeloma Future Perspectives

19. Multiple Myeloma Analyst Review

20. Appendix

21. Report Methodology

Request the sample PDF to get detailed insights about the Multiple Myeloma pipeline reports offerings: https://www.delveinsight.com/report-store/multiple-myeloma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=multiple-myeloma-pipeline-2025-key-clinical-innovations-from-over-75-global-leaders-delveinsight-highlighted-companies-include-casi-pharmaceuticals-carsgen-therapeutics-cartesian-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.